Concord Medical Explores Cooperation on Proton Therapy Center Development in Uzbekistan
On October 15, 2026, a delegation from Med China Healthcare met with the Agency for the Development of the Medical and Pharmaceutical Industry of Uzbekistan to explore potential cooperation in establishing a proton therapy center in Uzbekistan.
On October 15, 2026, a delegation from Med China Healthcare met with the Agency for the Development of the Medical and Pharmaceutical Industry of Uzbekistan to explore potential cooperation in establishing a proton therapy center in Uzbekistan. Both parties agreed to establish a joint working group to further assess the project and develop a potential implementation plan.
Abdulla Azizov, Director of the Agency for the Development of the Medical and Pharmaceutical Industry of Uzbekistan, met with the Med China Healthcare delegation led by President Jiang Wei..
During the meeting, the two sides discussed the prospects for developing a proton therapy center, the potential introduction of advanced radiation therapy technologies, and the application of Med China Healthcare's experience in developing and operating specialized cancer care facilities. They also exchanged views on key aspects of the proposed project, including potential cooperation models, financing arrangements, government support policies, and supporting infrastructure development.
The proposed center aims to strengthen local cancer care capabilities by exploring access to advanced radiation therapy technologies. It could also create opportunities to provide specialized cancer treatment services to patients from other Central Asian countries in the future.
At the conclusion of the meeting, both parties agreed to establish a joint working group to further refine the project proposal and develop an implementation roadmap, laying the groundwork for continued discussions and potential cooperation..
The meeting marks a positive step in Med China Healthcare's international healthcare collaboration efforts. It also creates an opportunity for the group to draw on its experience in proton therapy and specialized cancer hospital management while exploring new healthcare partnerships across Central Asia.
As discussions progress, the proposed initiative could contribute to the development of regional cancer care capabilities and expand opportunities for international collaboration in advanced radiotherapy.